Bristol Myers' Opdivo scores priority review in common bladder cancer, marking latest win in PD-1 battle with Keytruda
Two months after Bristol Myers Squibb announced Opdivo nearly doubled the average length of time patients with a common bladder cancer lived without disease recurrence, regulators have said they’ll give the PD-1 blockbuster an expedited look.
The FDA has granted priority review to Opdivo as an adjuvant treatment in muscle-invasive urothelial cancer, Bristol Myers said on Friday, marking the latest win in the pharma’s bid to outshine Merck’s superstar I/O Keytruda. The agency tapped Sept. 3 for a PDUFA date.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.